Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 8/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192005 | 0.90 | TRPV4 (0.47) | SYKCSF1RFLT3GRM5TRPV4 | |
| Trifluoroacetic Acid SCHEMBL2461325 | 0.89 | ROCK1 (0.41) | SYKGRM5TRPV4HRH4HRH3 | |
| SCHEMBL191004 | 0.81 | GRM5 (0.43) | SYKGRM5TRPV4GAA | |
| SCHEMBL190625 | 0.80 | GRM5 (0.51) | SYKGRM5TRPV4 | |
| SCHEMBL192164 | 0.79 | ROCK1 (0.48) | GRM5TRPV4ROCK1 | |
| SCHEMBL190612 | 0.77 | GPR119 (0.44) | SYK | |
| SCHEMBL190059 | 0.73 | CHEK2 (0.46) | SYKGRM5 | |
| SCHEMBL2658979 | 0.72 | TRPV4 (0.40) | SYKGRM5TRPV4GAA | |
| SCHEMBL191227 | 0.72 | TRPV4 (0.43) | GRM5TRPV4GAA | |
| SCHEMBL191226 | 0.72 | TRPV4 (0.43) | GRM5TRPV4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986645-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | SYK 3740/4885CSF1R 2024/4885FLT3 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.